EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control

Katherine Tuttle, André Scheen and Norbert Stefan discuss the benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control at EASD TV during #EASD2023. Are SGLT2 inhibitors and GLP-1 receptor agonists also beneficial for heart, kidney and liver disease?
#diabetes #cardiovasculardisease #chronickidneydisease #liverdisease

[@maxra1]

SGLT2 inhibitors are a good drug for prevention for non diabetic and with normal heart and kidney status?